Notice Number: NOT-HL-16-447
Key Dates
Release Date: October 13, 2016
RFA-TR-16-017
Issued by
National Heart, Lung, and Blood Institute (NHLBI)
Purpose
The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in RFA-TR-16-017 Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing (UG3/UH3)."
The following sections of RFA-TR-16-017 have been updated to reflect the participation of NHLBI in this FOA.
Part 1. Overview Information
Components of Participating Organizations
National Center for Advancing Translational Sciences (NCATS)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Environmental Health Sciences (NIEHS)
National Institute of Neurological Disorders and Stroke (NINDS)
Office of Research on Women’s Health (ORWH)
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Heart, Lung, and Blood Institute (NHLBI)
Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.350, 93.846, 93.865, 93.121, 93.847, 93.113, 93.853, 93.313, 93.286; 93.837, 93.838, 93.839, 93.840, 93.233
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Studies of Particular Interest
Current Language
Circulatory:
- Diseases of the circulatory system, including vascular malformations and stroke; lymphatic system , coronary heart diseases; blood diseases and disorders
Revised Language
Circulatory:
- Diseases of the circulatory system, including vascular malformations and stroke; lymphatic system , coronary heart diseases; blood diseases and disorders
- Effect of fluid flow, tissue-tissue interactions, and other mechanical and electrical cues on heart, lung or blood disease development
- Effect of spatial diffusive gradients on angiogenic sprouting.
- Disease models that include the lymphatic system and integration of innate and adaptive immune/inflammatory components.
Current Language:
Respiratory:
- Disease models of pulmonary hypertension, cystic fibrosis, bronchiospasm, asthma
- Disease models that would enable evaluation of exposures to respiratory pathogens, smoke inhalation or inhalation of toxic substances
Revised Language:
Respiratory:
- Disease models of pulmonary hypertension, cystic fibrosis, bronchiospasm, asthma
- Disease models that would enable evaluation of exposures to respiratory pathogens, smoke inhalation or inhalation of toxic substances
- Effect of mechanical forces of breathing on lung disease development, especially pulmonary edema
Current Language:
Desired model characteristics may include, but are not limited to the following:
- Innovative and creative approaches using tissue-on-chips technology towards 3-D models that include relevant anatomical and cellular elements
- Integration of proposed disease models with other organ systems to understand how tissue interactions influence disease pathogenesis, comorbidities, and treatment
- Inclusion of immune elements (e.g., lymphocytes, macrophages, neutrophils, or mucosa-associated lymphoid tissue)
- Inclusion of site-specific microbiota, where appropriate
- Accurate reflection of human host - pathogen interactions, where appropriate
- Capacity to test biomarkers or candidate therapeutics
- Development of markers or readouts to confirm that the model(s) of interest mimic human disease
- Applying genome manipulation strategies, such as CRISPR/Cas9, Talen and Zinc-finger to introduce relevant variants
Revised Language:
Desired model characteristics may include, but are not limited to the following:
- Innovative and creative approaches using tissue-on-chips technology towards 3-D models that include relevant anatomical and cellular elements
- Integration of proposed disease models with other organ systems to understand how tissue interactions influence disease pathogenesis, comorbidities, and treatment
- Inclusion of immune elements (e.g., lymphocytes, macrophages, neutrophils, or mucosa-associated lymphoid tissue)
- Inclusion of site-specific microbiota, where appropriate
- Accurate reflection of human host - pathogen interactions, where appropriate
- Capacity to test biomarkers or candidate therapeutics
- Development of markers or readouts to confirm that the model(s) of interest mimic human disease
- Applying genome manipulation strategies, such as CRISPR/Cas9, Talen and Zinc-finger to introduce relevant variants
- Models that can be used in situations where a clinical trial is unlikely to be done, especially to identify variables that may have the greatest impact on the precision of a model, and that may aid management strategies for rarer or pediatric diseases
Section II. Award Information
Funds Available and Anticipated Number of Awards
NHLBI intends to commit up to $3,000,000 in total costs per year for fiscal years 2017 through 2021 to fund up to two awards.
Section VII. Agency Contacts
Scientific/Research Contact(s)
Martha S. Lundberg, PhD
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0513
Email: [email protected]
Financial/Grants Management Contact(s)
Ronald Caulder
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0148
Email: [email protected]
All other aspects of this FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Martha S. Lundberg, PhD
National Heart, Lung and Blood Institute (NHLBI)
Telephone: 301-435-0513
Email: [email protected]
and Human Services (HHS)
